<DOC>
	<DOCNO>NCT01054924</DOCNO>
	<brief_summary>The purpose study evaluate efficacy ( i.e . reach cecum ) safety Invendo C20 Colonoscopy System</brief_summary>
	<brief_title>Performance Study Invendo C20 Colonoscope System Colorectal Cancer Screening</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>1 . Screenees , i.e . asymptomatic person willing undergo screening colonoscopy , average risk colorectal cancer 2 . Age 5075 year 3 . Signed informed consent 1 . Family personal history colorectal neoplasia include familial adenomatous polyposis ( FAP ) hereditary nonpolyposis colorectal cancer 2 . Prior colonoscopy within precede 10 year 3 . A suspected diagnosis inflammatory bowel disease , bowel obstruction , acute diverticulitis , know severe diverticulosis know large bowel disease 4 . Clinically significant cardiovascular pulmonary disease 5 . Gastrointestinaltract related symptom , complaint diseases suggest performance colonoscopy ( screen case ) 6 . Cancer life threaten disease significant chronic condition 7 . Blood clot disorder /or anticoagulant therapy include aspirin within last 7 day 8 . Known pregnancy positive screening pregnancy test 9 . Previous abdominal surgery except uncomplicated cholecystectomy , appendectomy minor pelvic surgery ( e.g . hernia repair , oophorectomy ) 10 . Morbid obesity ( BMI &gt; 40 ) 11 . Clinically significant abnormal screen laboratory finding 12 . Clinically significant abnormal screen ECG finding 13 . Drug abuse alcoholism 14 . Inability screenee adequately communicate 15 . Screenees custodial care 16 . Participation clinical study within last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>